Celia Morgan

Head of Ketamine Assisted Psychotherapy for Addiction at Awakn Life Sciences
On the record
Represented by:

Professor Celia Morgan, Awakn Life Science’s Head of Ketamine-Assisted Psychotherapy for Addiction, is one of the leading figures advancing the renaissance of psychedelic medicine. Most recently,Celia completed a phase II a/b study investigating ketamine-assisted psychotherapy for alcohol use disorder. The results for her Ketamine for Reduction of Alcoholic Relapse (KARE) study were published in the American Journal of Psychiatry and found an 86% abstinence rate compared to 2% before the trial. In addition to addressing alcoholism, Celia is also examining how psychedelics may modulate memories and hence address gambling addiction, the first such study using psychedelics to target behavioral addictions.

Celia is also a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. She completed her undergraduate degree and Ph.D at University College London (UCL) and completed a scholarship programme at Yale University. After competing her Ph.D, Celia worked at University of Melbourne as a visiting research fellow, returning to UCL for a fellowship and then Lectureship. She joined University of Exeter as a Senior Lecturer in 2013 and was given a Chair in Psychopharmacology in 2015.

Celia also holds an Honorary Readership at University College London. She is academic lead for both Exeter Translational Addiction Partnership (ETAP) and Ketamine for Reduction of Alcoholic Relapse (KARE). A long-time researcher of ketamine-assisted psychotherapy, Celia was recently named to Insider’s 16 Most Influential Women in Psychedelics list.

Sign up to view all